An observational study from eastern India on survival of patients treated with 1st line chemoimmunotherapy or chemotherapy+/- Cetuximab in metastatic, recurrent & inoperable head and neck cancers (ESMO Asia 2026) - Oct 1, 2026 - Abstract #618eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Observational data • Head and Neck Cancer • Oncology • Solid Tumor
|
|
Anirban Ghosh; Amit D. Dwary; Indranil Ghosh; Joydeep Ghosh
|